Novartis AG Registered Shares
NOVN: XSWX (CHE)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CHF 12.00 | Nstl | Myckdpgrw |
Novartis: Sandoz Spinoff Leaves a Well-Positioned Branded Drug Company
Following the Sandoz spinoff, we are lowering our Novartis fair value estimate to $92/CHF 85 for the ADR and local shares, respectively. We are maintaining our wide moat rating for Novartis as we believe the firm remains well-positioned to develop the next generation of innovative drugs, which is the core pillar of its wide moat. The loss of the more commoditized generic business of Sandoz will not likely affect the core branded drug division.